Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

What is the impact of socioeconomic status on multiple sclerosis?

Conway DS.

Neurology. 2019 Mar 26;92(13):e1536-e1539. doi: 10.1212/WNL.0000000000007166. No abstract available.

PMID:
30910951
2.

Prognostic factors of disability in relapsing remitting multiple sclerosis.

Briggs FBS, Thompson NR, Conway DS.

Mult Scler Relat Disord. 2019 May;30:9-16. doi: 10.1016/j.msard.2019.01.045. Epub 2019 Jan 29.

PMID:
30711764
3.

Cardiovascular conditions in persons with multiple sclerosis, neuromyelitis optica and transverse myelitis.

Saroufim P, Zweig SA, Conway DS, Briggs FBS.

Mult Scler Relat Disord. 2018 Oct;25:21-25. doi: 10.1016/j.msard.2018.07.011. Epub 2018 Jul 10.

PMID:
30014877
4.

Patient-Reported Disease-Modifying Therapy Adherence in the Clinic: A Reliable Metric?

Conway DS, Cecilia Vieira M, Thompson NR, Parker KN, Meng X, Fox RJ.

Mult Scler J Exp Transl Clin. 2018 May 23;4(2):2055217318777894. doi: 10.1177/2055217318777894. eCollection 2018 Apr-Jun.

5.

Multiple Sclerosis: Unprecedented Progress But Significant Challenges Ahead.

Conway DS, Hua LH, Cohen JA.

Neurotherapeutics. 2017 Oct;14(4):832-834. doi: 10.1007/s13311-017-0576-1. No abstract available.

6.

Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis.

Chaudhry BZ, Cohen JA, Conway DS.

Neurotherapeutics. 2017 Oct;14(4):859-873. doi: 10.1007/s13311-017-0565-4. Review.

7.

Survey-based assessment of the relationship between cognitive impairment and mentally stimulating activity in multiple sclerosis.

Prager BC, Nowacki AS, Conway DS.

Neurol Res. 2017 Sep;39(9):773-778. doi: 10.1080/01616412.2017.1348679. Epub 2017 Jul 5.

PMID:
28679344
8.

A case of presumed herpes keratouveitis in a patient treated with fingolimod.

Ayers MC, Conway DS.

Mult Scler J Exp Transl Clin. 2016 Jun 3;2:2055217316652907. doi: 10.1177/2055217316652907. eCollection 2016 Jan-Dec.

9.

Lack of magnetic resonance imaging lesion activity as a treatment target in multiple sclerosis: An evaluation using electronically collected outcomes.

Conway DS, Thompson NR, Cohen JA.

Mult Scler Relat Disord. 2016 Sep;9:129-34. doi: 10.1016/j.msard.2016.07.017. Epub 2016 Jul 27.

PMID:
27645360
10.

Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course.

Conway DS, Thompson NR, Cohen JA.

Mult Scler. 2017 Feb;23(2):277-285. doi: 10.1177/1352458516650512. Epub 2016 Jul 11.

PMID:
27230791
11.

COL4A1 gene mutation--beyond a vascular syndrome.

John S, Jehi L, Manno EM, Conway DS, Uchino K.

Seizure. 2015 Sep;31:19-21. doi: 10.1016/j.seizure.2015.06.014. Epub 2015 Jul 4. No abstract available.

12.

Natalizumab and fingolimod: insight into their relative efficacies in clinical practice.

Conway DS, Cohen JA.

Mult Scler. 2014 Sep;20(10):1280-1. doi: 10.1177/1352458514535283. No abstract available.

PMID:
25160120
13.

Factors associated with clinically significant increased walking time in multiple sclerosis: results of a survival analysis of short-term follow-up data from a clinical database.

Miller DM, Thompson NR, Cohen JA, Fox RJ, Hartman J, Schwetz K, Conway DS, Rudick RA.

Mult Scler. 2015 Apr;21(4):457-65. doi: 10.1177/1352458514544536. Epub 2014 Aug 11.

PMID:
25112816
14.

Long term benefit of multiple sclerosis treatment: an investigation using a novel data collection technique.

Conway DS, Miller DM, O'Brien RG, Cohen JA.

Mult Scler. 2012 Nov;18(11):1617-24. doi: 10.1177/1352458512449681. Epub 2012 May 31.

PMID:
22653659
15.

Multiple sclerosis: Mechanisms of disability accumulation in multiple sclerosis.

Conway DS, Cohen JA.

Nat Rev Neurol. 2010 Dec;6(12):654-5. doi: 10.1038/nrneurol.2010.175.

PMID:
21131915
16.

Inverse association of PPARĪ³ agonists use and high grade glioma development.

Grommes C, Conway DS, Alshekhlee A, Barnholtz-Sloan JS.

J Neurooncol. 2010 Nov;100(2):233-9. doi: 10.1007/s11060-010-0185-x. Epub 2010 May 5.

PMID:
20443132
17.

A longitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation: the Rotterdam Study 1990-1999.

Heeringa J, Conway DS, van der Kuip DA, Hofman A, Breteler MM, Lip GY, Witteman JC.

J Thromb Haemost. 2006 Sep;4(9):1944-9. Epub 2006 Jul 5.

19.

Atrial fibrillation, the prothrombotic state, inflammation, and gender.

Conway DS, Lip GY.

Am J Cardiol. 2005 Mar 15;95(6):819. No abstract available.

PMID:
15757625
20.

Inflammation, arrhythmia burden and the thrombotic consequences of atrial fibrillation.

Conway DS, Lip GY.

Eur Heart J. 2004 Oct;25(19):1761. No abstract available.

PMID:
15451156
21.

Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation.

Conway DS, Buggins P, Hughes E, Lip GY.

Am Heart J. 2004 Sep;148(3):462-6.

PMID:
15389233
22.
23.

Further insights into the prothrombotic state in mitral stenosis and atrial flutter.

Conway DS, Lip GY.

Chest. 2004 Jun;125(6):2361-2; author reply 2362-3. No abstract available.

PMID:
15189964
24.

Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation.

Conway DS, Buggins P, Hughes E, Lip GY.

J Am Coll Cardiol. 2004 Jun 2;43(11):2075-82.

26.
27.

Ethnicity in relation to atrial fibrillation and stroke (the West Birmingham Stroke Project).

Conway DS, Lip GY.

Am J Cardiol. 2003 Dec 15;92(12):1476-9.

PMID:
14675592
28.

Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: relationship to treatment and prognosis.

Chin BS, Conway DS, Chung NA, Blann AD, Gibbs CR, Lip GY.

Blood Coagul Fibrinolysis. 2003 Sep;14(6):515-21.

PMID:
12960603
29.
30.

Atrial fibrillation and the prothrombotic state in the elderly: the Rotterdam Study.

Conway DS, Heeringa J, Van Der Kuip DA, Chin BS, Hofman A, Witteman JC, Lip GY.

Stroke. 2003 Feb;34(2):413-7.

PMID:
12574552
31.

Antithrombotic therapy for atrial fibrillation.

Lip GY, Hart RG, Conway DS.

BMJ. 2002 Nov 2;325(7371):1022-5. Review. No abstract available.

33.

Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor?

Chung NA, Belgore F, Li-Saw-Hee FL, Conway DS, Blann AD, Lip GY.

Stroke. 2002 Sep;33(9):2187-91.

PMID:
12215585
34.
35.

New antiarrhythmic agents for atrial fibrillation.

Conway DS, Lip GY.

Curr Opin Investig Drugs. 2001 Jan;2(1):87-92. Review. No abstract available.

PMID:
11527018
36.

Systemic thromboembolism in atrial fibrillation.

Makin AJ, Conway DS, Lip GY.

Arch Intern Med. 2001 Aug 13-27;161(15):1920-4. No abstract available.

PMID:
11493151
37.

Anticoagulation and atrial fibrillation.

Conway DS, Lip GY.

Postgrad Med J. 2001 Jul;77(909):487; author reply 488. No abstract available.

38.
39.

Atopic eczema and staphylococcal endocarditis: time to recognize an association?

Conway DS, Taylor AD, Burrell CJ.

Hosp Med. 2000 May;61(5):356-7. No abstract available.

PMID:
10953745
40.

The nurse liaison.

Conway DS.

Todays OR Nurse. 1986 Oct;8(10):31-3. No abstract available.

PMID:
3641494

Supplemental Content

Loading ...
Support Center